Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)

This study has been completed.
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI) Identifier:
First received: October 27, 1999
Last updated: March 22, 2016
Last verified: August 2006
The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented.

Condition Intervention Phase
Respiratory Distress Syndrome, Adult
Lung Diseases
Procedure: Low Tidal Volume Ventilation
Procedure: Positive End-Expiratory Pressure
Drug: Lysofylline
Drug: Methylprednisolone
Drug: Ketoconazole
Procedure: Fluid Management
Procedure: Pulmonary Artery Catheter
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Factorial Assignment
Primary Purpose: Treatment
Official Title: Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)

Resource links provided by NLM:

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Primary Outcome Measures:
  • Vary by protocol

Study Start Date: September 1994
Study Completion Date: July 2004
  Show Detailed Description


Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women
  • 13 years of age or older
  • ARDS or risk factors for ARDS (patients will be considered at risk if they are critically ill and have trauma, sepsis, shock, pneumonia, inhalation injury, drug overdose, pancreatitis, or hypertransfusion)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000579

  Show 21 Study Locations
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Edward Abraham, MD University of Colorado, Denver
Principal Investigator: Antonio Anzueto, MD University of Texas
Principal Investigator: Roy Brower, MD Johns Hopkins University
Principal Investigator: Alfred F. Connors, MD University of Virginia
Principal Investigator: Bennett P. deBoisblanc, MD Louisiana State University Health Sciences Center in New Orleans
Principal Investigator: Bennett P. deBoisblanc, MD Louisiana State University Health Science Center
Principal Investigator: Michael Donahoe, MD University of Pittsburgh
Principal Investigator: Kalpalatha K. Guntupalli, MD Baylor College of Medicine
Principal Investigator: Robert D. Hite, MD Wake Forest University
Principal Investigator: Robert D. Hite, MD Wake Forest School of Medicine
Principal Investigator: Rolf Hubmayr, MD Mayo Clinic
Principal Investigator: Neil MacIntyre, MD Duke University
Principal Investigator: Michael A. Matthay, MD University of California, San Francisco
Principal Investigator: Alan Morris, MD Latter Day Saints Hospital
Principal Investigator: Michael J. Murray Mayo Foundation
Principal Investigator: James A. Russell, MD University of British Columbia
Principal Investigator: Gregory A. Schmidt, MD, FCCP University of Chicago
Principal Investigator: David A. Schoenfeld, PhD Massachusetts General Hospital
Principal Investigator: Jay S. Steingrub, MD, FCCP Baystate Medical Center
Principal Investigator: Arthur Wheeler, MD Vanderbilt University
Principal Investigator: Herbert Wiedemann, MD Cleveland Clinic Lerner College of Medicine
  More Information

Additional Information:

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00000579     History of Changes
Other Study ID Numbers: 217  N01HR16146  N01HR16147  N01HR16148  N01HR16149  N01HR16150  N01HR16151  N01HR16152  N01HR16153  N01HR16154  N01HR16155  N01HR46054  N01HR46055  N01HR46056  N01HR46057  N01HR46058  N01HR46059  N01HR46060  N01HR46061  N01HR46062  N01HR46063  N01HR46064  N01HR56165  N01HR56166  N01HR56167  N01HR56168  N01HR56169  N01HR56170  N01HR56171  N01HR56172  N01HR56173  N01HR56174  N01HR56175  N01HR56176  N01HR56179 
Study First Received: October 27, 1999
Last Updated: March 22, 2016
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Acute Lung Injury
Lung Diseases
Respiratory Distress Syndrome, Adult
Respiratory Distress Syndrome, Newborn
Infant, Newborn, Diseases
Infant, Premature, Diseases
Lung Injury
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Methylprednisolone Hemisuccinate
Methylprednisolone acetate
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents
Peripheral Nervous System Agents processed this record on May 25, 2016